Lokon Pharma AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Private
- Established
- 2015-01-01
- Employees
- 1
- Market Cap
- -
- Website
- https://lokonpharma.com
Clinical Trials
3
Active:1
Completed:2
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma
Phase 1
Completed
- Conditions
- Malignant Melanoma
- Interventions
- Genetic: delolimogene mupadenorepvec
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Lokon Pharma AB
- Target Recruit Count
- 26
- Registration Number
- NCT04123470
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Baylor St Luke's Medical Center, Houston, Texas, United States
🇸🇪Uppsala University Hospital, Uppsala, Sweden
Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
Phase 1
Completed
- Conditions
- Pancreatic AdenocarcinomaOvarian CancerBiliary CarcinomaColorectal Cancer
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Lokon Pharma AB
- Target Recruit Count
- 47
- Registration Number
- NCT03225989
- Locations
- 🇸🇪
Karolinska University Hospital, Huddinge, Stockholm, Sweden
🇸🇪Uppsala University Hospital, Uppsala, Sweden
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
Phase 1
Active, not recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Lokon Pharma AB
- Target Recruit Count
- 51
- Registration Number
- NCT02705196
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸Baylor St Luke's Medical Center, Houston, Texas, United States
News
No news found